Recently many lawsuits have been filed against Fresenius Medical Care, one of the leading producers of dialysis treatment products and services in the world. These lawsuits have been filed after allegations arose that the company was aware of heart attack and death risks associated with two of its dialysis solutions: GranuFlo and NaturaLyte. Both of these products are acid concentrates used in hemodialysis treatment for acute and chronic renal failure. Following reports of numerous injuries and deaths (as well as a 2012 FDA recall), many lawsuits have been filed in regards to these harmful and defective dialysis products.
GranuFlo, unlike many other rival products, contains acetic acid and sodium acetate. Another Fresenius product NaturaLyte, also contains these ingredients as well. Because a patient’s body turns sodium acetate into bicarbonate, the result is that the patients bicarbonate levels are elevated significantly higher than is intended by the amount prescribed. These unexpectedly high bicarbonate levels can be dangerous because they put the patient at a risk of metabolic alkalosis, a metabolic condition. In metabolic alkalosis, the pH levels of a person’s body tissues are much higher than the normal range, and it can be very dangerous. Metabolic alkalosis can result in GranuFlo Heart Attacks and death. Heart Attacks are the leading complication in GranuFlo dialysis treatment, and patients treated with Granuflo are believed to have between 6 and 8 times the risk of heart attacks when compared to other dialysis treatment products.
GranuFlo (as well as another Fresenius dialysis product, NaturaLyte was the subject of a class one FDA recall earlier this year. According to the FDA website, a Class I recall is defined as “a situation in which there is a reasonable probability that the use of or exposure to a volative product will cause serious adverse health consequences or death.” In this case, the violative product is GranuFlo, and the adverse health consequences included: hypoxemia, hypercapnia, cardiac arrhythmia, and hypokalemia, low blood pressure, which may culminate in cardiopulmonary arrest or heart attacks. The use of GranuFlo in dialysis has also been linked to as many as 941 deaths in 2010 alone.
Have you or a loved one suffered from a heart attack after treatment with GranuFlo or another Fresenius dialysis solution? If so, you may be legally entitled to financial compensation for your related physical, emotional, and financial injuries. Call the Willis Law Firm for a free attorney consultation to evaluate your potential GranuFlo Heart Attack claim. All dialysis clients are represented on a contingency fee basis, so you will not be billed any legal fees unless a recovery is obtained. Call today; we are now reviewing GranuFlo cases nationwide.